MEA G-CSF PEG-G-CSF市場 - 産業動向と2030年までの予測MEA G-CSF PEG-G-CSF Market - Industry Trends and Forecast to 2030 中東とアフリカのG-CSF/PEG-G-CSF市場は、2023年から2030年にかけて4.1%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は... もっと見る
サマリー中東とアフリカのG-CSF/PEG-G-CSF市場は、2023年から2030年にかけて4.1%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。市場セグメンテーションを行います: 中東アフリカのG-CSF/PEG-G-CSF市場、適応症別(好中球減少症、腫瘍、慢性・自己免疫疾患、血液疾患、成長調和不全、その他)、投与量(単剤、配合剤)、投与経路(静脈内、皮下)、包装(単剤バイアル、プレフィルドシリンジ)、エンドユーザー(病院・クリニック、研究・学術機関、外来手術センター、その他)、流通チャネル(病院薬局、オンライン薬局、小売薬局、その他)、国(南アフリカ、サウジアラビア、エジプト、イスラエル、UAE、クウェート、オマーン、中東・アフリカのその他)の産業動向と2030年までの予測 中東・アフリカのG-CSF/PEG-G-CSF市場の成長に寄与する主な要因としては、以下のものが挙げられます: - 血液がんやがん疾患の増加 - 発熱性好中球減少症の増加例 市場のプレイヤー: 中東・アフリカのG-CSF/PEG-G-CSF市場で活動している主要な市場関係者は以下の通りです: - ルパン - ビオシダス - USVプライベート・リミテッド - ヴィアトリス社 - バイオコン - フレゼニウス・カビAG - アムジェン社 - ファイザー株式会社 - サンド・インターナショナル社 - ドクター・レディーズ・ラボラトリーズ・リミテッド(Dr. Reddy's Laboratories Ltd. - アコードヘルスケア - ナップ・ファーマシューティカルズ・リミテッド - インタス・ファーマシューティカルズ・リミテッド - ムンディファーマ・インターナショナル - テバ・ファーマシューティカル・インダストリーズ社 - 協和キリン株式会社 目次TABLE OF CONTENTS1 INTRODUCTION 24 1.1 OBJECTIVES OF THE STUDY 24 1.2 MARKET DEFINITION 24 1.3 OVERVIEW OF MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 24 1.4 LIMITATIONS 26 1.5 MARKETS COVERED 26 2 MARKET SEGMENTATION 29 2.1 MARKETS COVERED 29 2.2 GEOGRAPHICAL SCOPE 30 2.3 YEARS CONSIDERED FOR THE STUDY 31 2.4 CURRENCY AND PRICING 31 2.5 DBMR TRIPOD DATA VALIDATION MODEL 32 2.6 MULTIVARIATE MODELLING 35 2.7 TYPE LIFELINE CURVE 35 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36 2.9 DBMR MARKET POSITION GRID 37 2.10 MARKET END USER COVERAGE GRID 38 2.11 VENDOR SHARE ANALYSIS 39 2.12 SECONDARY SOURCES 40 2.13 ASSUMPTIONS 40 3 EXECUTIVE SUMMARY 41 4 PREMIUM INSIGHTS 44 4.1 PESTEL ANALYSIS 45 4.2 PORTER’S FIVE FORCES 46 4.3 MIDDLE EAST & AFRICA G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 47 4.4 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 48 4.5 STRATEGIES TO THE ENTER THE MARKET 48 4.5.1 JOINT VENTURE (PARTNERSHIPS): 48 4.5.2 ACQUISITION: 48 4.5.3 LINE EXPANSION VIA COLLABORATION: 48 4.5.4 PRODUCT APPROVAL: 49 4.5.5 PRODUCT LAUNCH: 49 4.5.6 GEOGRAPHIC EXPANSION: 49 4.5.7 COST LEADERSHIP: 50 4.5.8 PRODUCT DEVELOPMENT: 50 4.6 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 51 4.6.1 PATENT ANALYSIS 51 4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 52 4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52 4.6.4 THERAPEUTIC ASSESSMENT 52 4.6.5 KEY PRICING STRATEGIES 53 4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 53 4.6.7 CONCLUSION 53 4.7 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 54 5 EPIDEMIOLOGY 55 6 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET: REGULATIONS 58 7 MARKET OVERVIEW 61 7.1 DRIVERS 63 7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 63 7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 64 7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 65 7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 66 7.2 RESTRAIN 67 7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 67 7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 68 7.3 OPPORTUNITIES 69 7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 69 7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 69 7.4 CHALLENGES 70 7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 70 7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 70 8 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION 71 8.1 OVERVIEW 72 8.2 NEUTROPENIA 76 8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 77 8.2.2 SEVERE CHRONIC NEUTROPENIA 77 8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 77 8.2.4 NEUTROPENIA IN HIV PATIENTS 77 8.2.5 CLOZAPINE INDUCED NEUTROPENIA 77 8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 77 8.2.7 CONGENITAL NEUTROPENIA 77 8.3 ONCOLOGY 78 8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 78 8.3.2 OTHERS 79 8.4 CHRONIC AND AUTO IMMUNE DISEASES 79 8.5 BLOOD DISORDERS 79 8.6 GROWTH HORMONE DEFICIENCY 80 8.7 OTHERS 81 9 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 82 9.1 OVERVIEW 83 9.2 MONO 86 9.3 COMBINATION 87 10 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 88 10.1 OVERVIEW 89 10.2 SUBCUTANEOUS 92 10.3 INTRAVENOUS 93 11 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 94 11.1 OVERVIEW 95 11.2 PRE FILLED SYRINGES 98 11.3 SINGLE USE VIALS 99 12 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY END USER 100 12.1 OVERVIEW 101 12.2 HOSPITALS AND CLINICS 104 12.3 RESEARCH & ACADEMIC INSTITUTES 104 12.4 AMBULATORY SURGICAL CENTERS 105 12.5 OTHERS 106 13 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 107 13.1 OVERVIEW 108 13.2 HOSPITALS PHARMACY 111 13.3 RETAIL PHARMACY 111 13.4 ONLINE PHARMACY 112 13.5 OTHERS 113 14 MIDDLE EAST & AFRICA G-CSF/PEG-G-CSF MARKET, BY REGION 114 14.1 MIDDLE EAST AND AFRICA 115 14.1.1 SOUTH AFRICA 121 14.1.2 SAUDI ARABIA 129 14.1.3 EGYPT 136 14.1.4 ISRAEL 144 14.1.5 UAE 151 14.1.6 KUWAIT 157 14.1.7 OMAN 164 15 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 171 15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 171 16 SWOT ANALYSIS 172 17 COMPANY PROFILE 173 17.1 PFIZER INC. 173 17.1.1 COMPANY SNAPSHOT 173 17.1.2 REVENUE ANALYSIS 174 17.1.3 COMPANY SHARE ANALYSIS 174 17.1.4 PRODUCT PORTFOLIO 175 17.1.5 RECENT DEVELOPMENTS 175 17.2 VIATRIS INC. 176 17.2.1 COMPANY SNAPSHOT 176 17.2.2 REVENUE ANALYSIS 176 17.2.3 COMPANY SHARE ANALYSIS 177 17.2.4 PRODUCT PORTFOLIO 177 17.2.5 RECENT DEVELOPMENT 177 17.3 AMGEN INC. 178 17.3.1 COMPANY SNAPSHOT 178 17.3.2 REVENUE ANALYSIS 178 17.3.3 COMPANY SHARE ANALYSIS 179 17.3.4 PRODUCT PORTFOLIO 179 17.3.5 RECENT DEVELOPMENTS 179 17.4 STADA ARZENEIMITTEL AG 181 17.4.1 COMPANY SNAPSHOT 181 17.4.2 COMPANY SHARE ANALYSIS 181 17.4.3 PRODUCT PORTFOLIO 182 17.4.4 RECENT DEVELOPMENT 182 17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 183 17.5.1 COMPANY SNAPSHOT 183 17.5.2 REVENUE ANALYSIS 183 17.5.3 COMPANY SHARE ANALYSIS 184 17.5.4 PRODUCT PORTFOLIO 184 17.5.5 RECENT DEVELOPMENTS 184 17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 185 17.6.1 COMPANY SNAPSHOT 185 17.6.2 PRODUCT PORTFOLIO 185 17.6.3 RECENT DEVELOPMENTS 185 17.7 ACCORD HEALTHCARE 186 17.7.1 COMPANY SNAPSHOT 186 17.7.2 PRODUCT PORTFOLIO 186 17.7.3 RECENT DEVELOPMENTS 186 17.8 AMNEAL PHARMACEUTICALS LLC. 187 17.8.1 COMPANY SNAPSHOT 187 17.8.2 REVENUE ANALYSIS 187 17.8.3 PRODUCT PORTFOLIO 188 17.8.4 RECENT DEVELOPMENTS 188 17.9 APOTEX INC. 189 17.9.1 COMPANY SNAPSHOT 189 17.9.2 PRODUCT PORTFOLIO 189 17.9.3 RECENT DEVELOPMENT 189 17.10 BIOCON 190 17.10.1 COMPANY SNAPSHOT 190 17.10.2 REVENUE ANALYSIS 190 17.10.3 PRODUCT PORTFOLIO 191 17.10.4 RECENT DEVELOPMENT 191 17.11 BIO SIDUS 192 17.11.1 COMPANY SNAPSHOT 192 17.11.2 PRODUCT PORTFOLIO 192 17.11.3 RECENT DEVELOPMENTS 192 17.12 CADILA PHARMACEUTICALS 193 17.12.1 COMPANY SNAPSHOT 193 17.12.2 PRODUCT PORTFOLIO 193 17.12.3 RECENT DEVELOPMENTS 193 17.13 COHERUS BIOSCIENCES 194 17.13.1 COMPANY SNAPSHOT 194 17.13.2 REVENUE ANALYSIS 194 17.13.3 PRODUCT PORTFOLIO 195 17.13.4 RECENT DEVELOPMENT 195 17.14 DR. REDDY’S LABORATORIES LTD 196 17.14.1 COMPANY SNAPSHOT 196 17.14.2 REVENUE ANALYSIS 196 17.14.3 PRODUCT PORTFOLIO 197 17.14.4 RECENT DEVELOPMENTS 197 17.15 FRESENIUS KABI AG 198 17.15.1 COMPANY SNAPSHOT 198 17.15.2 PRODUCT PORTFOLIO 198 17.15.3 RECENT DEVELOPMENT 198 17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 199 17.16.1 COMPANY SNAPSHOT 199 17.16.2 PRODUCT PORTFOLIO 199 17.16.3 RECENT DEVELOPMENTS 199 17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 200 17.17.1 COMPANY SNAPSHOT 200 17.17.2 PRODUCT PORTFOLIO 200 17.17.3 RECENT DEVELOPMENTS 200 17.18 INTAS PHARMACEUTICALS LTD. 201 17.18.1 COMPANY SNAPSHOT 201 17.18.2 PRODUCT PORTFOLIO 201 17.18.3 RECENT DEVELOPMENT 201 17.19 KASHIV BIOSCIENCES, LLC. 202 17.19.1 COMPANY SNAPSHOT 202 17.19.2 PRODUCT PORTFOLIO 202 17.19.3 RECENT DEVELOPMENT 202 17.20 KYOWA KIRIN CO., LTD. 203 17.20.1 COMPANY SNAPSHOT 203 17.20.2 REVENUE ANALYSIS 203 17.20.3 PRODUCT PORTFOLIO 204 17.20.4 RECENT DEVELOPMENT 204 17.21 LUPIN 205 17.21.1 COMPANY SNAPSHOT 205 17.21.2 REVENUE ANALYSIS 205 17.21.3 PRODUCT PORTFOLIO 206 17.21.4 RECENT DEVELOPMENT 206 17.22 MUNDIPHARMA INTERNATIONAL. 207 17.22.1 COMPANY SNAPSHOT 207 17.22.2 PRODUCT PORTFOLIO 207 17.22.3 RECENT DEVELOPMENT 207 17.23 NAPP PHARMACEUTICALS LIMITED 208 17.23.1 COMPANY SNAPSHOT 208 17.23.2 PRODUCT PORTFOLIO 208 17.23.3 RECENT DEVELOPMENT 208 17.24 RELIANCE LIFE SCIENCES 209 17.24.1 COMPANY SNAPSHOT 209 17.24.2 PRODUCT PORTFOLIO 209 17.24.3 RECENT DEVELOPMENTS 209 17.25 SANDOZ INTERNATIONAL GMBH 210 17.25.1 COMPANY SNAPSHOT 210 17.25.2 REVENUE ANALYSIS 210 17.25.3 PRODUCT PORTFOLIO 211 17.25.4 RECENT DEVELOPMENTS 211 17.26 SPECTRUM PHARMACEUTICALS, INC. 212 17.26.1 COMPANY SNAPSHOT 212 17.26.2 PRODUCT PORTFOLIO 212 17.26.3 RECENT DEVELOPMENT 212 17.27 USV PRIVATE LIMITED 213 17.27.1 COMPANY SNAPSHOT 213 17.27.2 PRODUCT PORTFOLIO 213 17.27.3 RECENT DEVELOPMENTS 213 18 QUESTIONNAIRE 214 19 RELATED REPORTS 217 図表リストLIST OF TABLESTABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 58 TABLE 2 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 75 TABLE 3 MIDDLE EAST & AFRICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 76 TABLE 4 MIDDLE EAST & AFRICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 76 TABLE 5 MIDDLE EAST & AFRICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 78 TABLE 6 MIDDLE EAST & AFRICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 78 TABLE 7 MIDDLE EAST & AFRICA CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 79 TABLE 8 MIDDLE EAST & AFRICA BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80 TABLE 9 MIDDLE EAST & AFRICA GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80 TABLE 10 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81 TABLE 11 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 85 TABLE 12 MIDDLE EAST & AFRICA MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 86 TABLE 13 MIDDLE EAST & AFRICA COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 87 TABLE 14 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 91 TABLE 15 MIDDLE EAST & AFRICA SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 92 TABLE 16 MIDDLE EAST & AFRICA INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 93 TABLE 17 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 97 TABLE 18 MIDDLE EAST & AFRICA PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 98 TABLE 19 MIDDLE EAST & AFRICA SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 99 TABLE 20 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 103 TABLE 21 MIDDLE EAST & AFRICA HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 104 TABLE 22 MIDDLE EAST & AFRICA RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 105 TABLE 23 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 105 TABLE 24 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 106 TABLE 25 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 110 TABLE 26 MIDDLE EAST & AFRICA HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 111 TABLE 27 MIDDLE EAST & AFRICA RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 112 TABLE 28 MIDDLE EAST & AFRICA ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 112 TABLE 29 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 113 TABLE 30 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 118 TABLE 31 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 118 TABLE 32 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 118 TABLE 33 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 118 TABLE 34 MIDDLE EAST AND AFRICA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119 TABLE 35 MIDDLE EAST AND AFRICA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119 TABLE 36 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 119 TABLE 37 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 120 TABLE 38 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 120 TABLE 39 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 120 TABLE 40 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 120 TABLE 41 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121 TABLE 42 SOUTH AFRICA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121 TABLE 43 SOUTH AFRICA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 122 TABLE 44 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 122 TABLE 45 SOUTH AFRICA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 122 TABLE 46 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 122 TABLE 47 SOUTH AFRICA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123 TABLE 48 SOUTH AFRICA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123 TABLE 49 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 123 TABLE 50 SOUTH AFRICA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123 TABLE 51 SOUTH AFRICA SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124 TABLE 52 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 124 TABLE 53 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124 TABLE 54 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 124 TABLE 55 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125 TABLE 56 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125 TABLE 57 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 125 TABLE 58 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125 TABLE 59 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125 TABLE 60 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126 TABLE 61 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 126 TABLE 62 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 126 TABLE 63 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126 TABLE 64 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126 TABLE 65 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127 TABLE 66 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127 TABLE 67 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 127 TABLE 68 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127 TABLE 69 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127 TABLE 70 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128 TABLE 71 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128 TABLE 72 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 129 TABLE 73 SAUDI ARABIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 129 TABLE 74 SAUDI ARABIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 130 TABLE 75 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 130 TABLE 76 SAUDI ARABIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 130 TABLE 77 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 130 TABLE 78 SAUDI ARABIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131 TABLE 79 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 131 TABLE 80 SAUDI ARABIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131 TABLE 81 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 131 TABLE 82 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132 TABLE 83 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 132 TABLE 84 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 132 TABLE 85 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132 TABLE 86 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 132 TABLE 87 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133 TABLE 88 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133 TABLE 89 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133 TABLE 90 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133 TABLE 91 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 133 TABLE 92 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134 TABLE 93 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134 TABLE 94 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134 TABLE 95 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134 TABLE 96 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134 TABLE 97 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134 TABLE 98 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135 TABLE 99 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 135 TABLE 100 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 135 TABLE 101 EGYPT G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 136 TABLE 102 EGYPT NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 136 TABLE 103 EGYPT ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 137 TABLE 104 EGYPT G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 137 TABLE 105 EGYPT MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 137 TABLE 106 EGYPT G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 137 TABLE 107 EGYPT SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138 TABLE 108 EGYPT G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 138 TABLE 109 EGYPT PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138 TABLE 110 EGYPT G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 138 TABLE 111 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139 TABLE 112 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 139 TABLE 113 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 139 TABLE 114 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139 TABLE 115 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140 TABLE 116 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140 TABLE 117 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140 TABLE 118 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140 TABLE 119 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140 TABLE 120 EGYPT G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 141 TABLE 121 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 141 TABLE 122 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141 TABLE 123 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 141 TABLE 124 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142 TABLE 125 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 142 TABLE 126 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 142 TABLE 127 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142 TABLE 128 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 143 TABLE 129 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 143 TABLE 130 ISRAEL G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 144 TABLE 131 ISRAEL NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 144 TABLE 132 ISRAEL ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 145 TABLE 133 ISRAEL G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 145 TABLE 134 ISRAEL MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 145 TABLE 135 ISRAEL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 145 TABLE 136 ISRAEL SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146 TABLE 137 ISRAEL INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146 TABLE 138 ISRAEL G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 146 TABLE 139 ISRAEL PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146 TABLE 140 ISRAEL G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 147 TABLE 141 ISRAEL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 147
SummaryMiddle East and Africa G-CSF/ PEG-G-CSF market is projected to register a substantial CAGR of 4.1% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Table of ContentsTABLE OF CONTENTS1 INTRODUCTION 24 1.1 OBJECTIVES OF THE STUDY 24 1.2 MARKET DEFINITION 24 1.3 OVERVIEW OF MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 24 1.4 LIMITATIONS 26 1.5 MARKETS COVERED 26 2 MARKET SEGMENTATION 29 2.1 MARKETS COVERED 29 2.2 GEOGRAPHICAL SCOPE 30 2.3 YEARS CONSIDERED FOR THE STUDY 31 2.4 CURRENCY AND PRICING 31 2.5 DBMR TRIPOD DATA VALIDATION MODEL 32 2.6 MULTIVARIATE MODELLING 35 2.7 TYPE LIFELINE CURVE 35 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36 2.9 DBMR MARKET POSITION GRID 37 2.10 MARKET END USER COVERAGE GRID 38 2.11 VENDOR SHARE ANALYSIS 39 2.12 SECONDARY SOURCES 40 2.13 ASSUMPTIONS 40 3 EXECUTIVE SUMMARY 41 4 PREMIUM INSIGHTS 44 4.1 PESTEL ANALYSIS 45 4.2 PORTER’S FIVE FORCES 46 4.3 MIDDLE EAST & AFRICA G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 47 4.4 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 48 4.5 STRATEGIES TO THE ENTER THE MARKET 48 4.5.1 JOINT VENTURE (PARTNERSHIPS): 48 4.5.2 ACQUISITION: 48 4.5.3 LINE EXPANSION VIA COLLABORATION: 48 4.5.4 PRODUCT APPROVAL: 49 4.5.5 PRODUCT LAUNCH: 49 4.5.6 GEOGRAPHIC EXPANSION: 49 4.5.7 COST LEADERSHIP: 50 4.5.8 PRODUCT DEVELOPMENT: 50 4.6 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 51 4.6.1 PATENT ANALYSIS 51 4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 52 4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52 4.6.4 THERAPEUTIC ASSESSMENT 52 4.6.5 KEY PRICING STRATEGIES 53 4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 53 4.6.7 CONCLUSION 53 4.7 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET 54 5 EPIDEMIOLOGY 55 6 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET: REGULATIONS 58 7 MARKET OVERVIEW 61 7.1 DRIVERS 63 7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 63 7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 64 7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 65 7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 66 7.2 RESTRAIN 67 7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 67 7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 68 7.3 OPPORTUNITIES 69 7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 69 7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 69 7.4 CHALLENGES 70 7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 70 7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 70 8 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION 71 8.1 OVERVIEW 72 8.2 NEUTROPENIA 76 8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 77 8.2.2 SEVERE CHRONIC NEUTROPENIA 77 8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 77 8.2.4 NEUTROPENIA IN HIV PATIENTS 77 8.2.5 CLOZAPINE INDUCED NEUTROPENIA 77 8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 77 8.2.7 CONGENITAL NEUTROPENIA 77 8.3 ONCOLOGY 78 8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 78 8.3.2 OTHERS 79 8.4 CHRONIC AND AUTO IMMUNE DISEASES 79 8.5 BLOOD DISORDERS 79 8.6 GROWTH HORMONE DEFICIENCY 80 8.7 OTHERS 81 9 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 82 9.1 OVERVIEW 83 9.2 MONO 86 9.3 COMBINATION 87 10 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 88 10.1 OVERVIEW 89 10.2 SUBCUTANEOUS 92 10.3 INTRAVENOUS 93 11 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 94 11.1 OVERVIEW 95 11.2 PRE FILLED SYRINGES 98 11.3 SINGLE USE VIALS 99 12 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY END USER 100 12.1 OVERVIEW 101 12.2 HOSPITALS AND CLINICS 104 12.3 RESEARCH & ACADEMIC INSTITUTES 104 12.4 AMBULATORY SURGICAL CENTERS 105 12.5 OTHERS 106 13 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 107 13.1 OVERVIEW 108 13.2 HOSPITALS PHARMACY 111 13.3 RETAIL PHARMACY 111 13.4 ONLINE PHARMACY 112 13.5 OTHERS 113 14 MIDDLE EAST & AFRICA G-CSF/PEG-G-CSF MARKET, BY REGION 114 14.1 MIDDLE EAST AND AFRICA 115 14.1.1 SOUTH AFRICA 121 14.1.2 SAUDI ARABIA 129 14.1.3 EGYPT 136 14.1.4 ISRAEL 144 14.1.5 UAE 151 14.1.6 KUWAIT 157 14.1.7 OMAN 164 15 MIDDLE EAST & AFRICA G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 171 15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 171 16 SWOT ANALYSIS 172 17 COMPANY PROFILE 173 17.1 PFIZER INC. 173 17.1.1 COMPANY SNAPSHOT 173 17.1.2 REVENUE ANALYSIS 174 17.1.3 COMPANY SHARE ANALYSIS 174 17.1.4 PRODUCT PORTFOLIO 175 17.1.5 RECENT DEVELOPMENTS 175 17.2 VIATRIS INC. 176 17.2.1 COMPANY SNAPSHOT 176 17.2.2 REVENUE ANALYSIS 176 17.2.3 COMPANY SHARE ANALYSIS 177 17.2.4 PRODUCT PORTFOLIO 177 17.2.5 RECENT DEVELOPMENT 177 17.3 AMGEN INC. 178 17.3.1 COMPANY SNAPSHOT 178 17.3.2 REVENUE ANALYSIS 178 17.3.3 COMPANY SHARE ANALYSIS 179 17.3.4 PRODUCT PORTFOLIO 179 17.3.5 RECENT DEVELOPMENTS 179 17.4 STADA ARZENEIMITTEL AG 181 17.4.1 COMPANY SNAPSHOT 181 17.4.2 COMPANY SHARE ANALYSIS 181 17.4.3 PRODUCT PORTFOLIO 182 17.4.4 RECENT DEVELOPMENT 182 17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 183 17.5.1 COMPANY SNAPSHOT 183 17.5.2 REVENUE ANALYSIS 183 17.5.3 COMPANY SHARE ANALYSIS 184 17.5.4 PRODUCT PORTFOLIO 184 17.5.5 RECENT DEVELOPMENTS 184 17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 185 17.6.1 COMPANY SNAPSHOT 185 17.6.2 PRODUCT PORTFOLIO 185 17.6.3 RECENT DEVELOPMENTS 185 17.7 ACCORD HEALTHCARE 186 17.7.1 COMPANY SNAPSHOT 186 17.7.2 PRODUCT PORTFOLIO 186 17.7.3 RECENT DEVELOPMENTS 186 17.8 AMNEAL PHARMACEUTICALS LLC. 187 17.8.1 COMPANY SNAPSHOT 187 17.8.2 REVENUE ANALYSIS 187 17.8.3 PRODUCT PORTFOLIO 188 17.8.4 RECENT DEVELOPMENTS 188 17.9 APOTEX INC. 189 17.9.1 COMPANY SNAPSHOT 189 17.9.2 PRODUCT PORTFOLIO 189 17.9.3 RECENT DEVELOPMENT 189 17.10 BIOCON 190 17.10.1 COMPANY SNAPSHOT 190 17.10.2 REVENUE ANALYSIS 190 17.10.3 PRODUCT PORTFOLIO 191 17.10.4 RECENT DEVELOPMENT 191 17.11 BIO SIDUS 192 17.11.1 COMPANY SNAPSHOT 192 17.11.2 PRODUCT PORTFOLIO 192 17.11.3 RECENT DEVELOPMENTS 192 17.12 CADILA PHARMACEUTICALS 193 17.12.1 COMPANY SNAPSHOT 193 17.12.2 PRODUCT PORTFOLIO 193 17.12.3 RECENT DEVELOPMENTS 193 17.13 COHERUS BIOSCIENCES 194 17.13.1 COMPANY SNAPSHOT 194 17.13.2 REVENUE ANALYSIS 194 17.13.3 PRODUCT PORTFOLIO 195 17.13.4 RECENT DEVELOPMENT 195 17.14 DR. REDDY’S LABORATORIES LTD 196 17.14.1 COMPANY SNAPSHOT 196 17.14.2 REVENUE ANALYSIS 196 17.14.3 PRODUCT PORTFOLIO 197 17.14.4 RECENT DEVELOPMENTS 197 17.15 FRESENIUS KABI AG 198 17.15.1 COMPANY SNAPSHOT 198 17.15.2 PRODUCT PORTFOLIO 198 17.15.3 RECENT DEVELOPMENT 198 17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 199 17.16.1 COMPANY SNAPSHOT 199 17.16.2 PRODUCT PORTFOLIO 199 17.16.3 RECENT DEVELOPMENTS 199 17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 200 17.17.1 COMPANY SNAPSHOT 200 17.17.2 PRODUCT PORTFOLIO 200 17.17.3 RECENT DEVELOPMENTS 200 17.18 INTAS PHARMACEUTICALS LTD. 201 17.18.1 COMPANY SNAPSHOT 201 17.18.2 PRODUCT PORTFOLIO 201 17.18.3 RECENT DEVELOPMENT 201 17.19 KASHIV BIOSCIENCES, LLC. 202 17.19.1 COMPANY SNAPSHOT 202 17.19.2 PRODUCT PORTFOLIO 202 17.19.3 RECENT DEVELOPMENT 202 17.20 KYOWA KIRIN CO., LTD. 203 17.20.1 COMPANY SNAPSHOT 203 17.20.2 REVENUE ANALYSIS 203 17.20.3 PRODUCT PORTFOLIO 204 17.20.4 RECENT DEVELOPMENT 204 17.21 LUPIN 205 17.21.1 COMPANY SNAPSHOT 205 17.21.2 REVENUE ANALYSIS 205 17.21.3 PRODUCT PORTFOLIO 206 17.21.4 RECENT DEVELOPMENT 206 17.22 MUNDIPHARMA INTERNATIONAL. 207 17.22.1 COMPANY SNAPSHOT 207 17.22.2 PRODUCT PORTFOLIO 207 17.22.3 RECENT DEVELOPMENT 207 17.23 NAPP PHARMACEUTICALS LIMITED 208 17.23.1 COMPANY SNAPSHOT 208 17.23.2 PRODUCT PORTFOLIO 208 17.23.3 RECENT DEVELOPMENT 208 17.24 RELIANCE LIFE SCIENCES 209 17.24.1 COMPANY SNAPSHOT 209 17.24.2 PRODUCT PORTFOLIO 209 17.24.3 RECENT DEVELOPMENTS 209 17.25 SANDOZ INTERNATIONAL GMBH 210 17.25.1 COMPANY SNAPSHOT 210 17.25.2 REVENUE ANALYSIS 210 17.25.3 PRODUCT PORTFOLIO 211 17.25.4 RECENT DEVELOPMENTS 211 17.26 SPECTRUM PHARMACEUTICALS, INC. 212 17.26.1 COMPANY SNAPSHOT 212 17.26.2 PRODUCT PORTFOLIO 212 17.26.3 RECENT DEVELOPMENT 212 17.27 USV PRIVATE LIMITED 213 17.27.1 COMPANY SNAPSHOT 213 17.27.2 PRODUCT PORTFOLIO 213 17.27.3 RECENT DEVELOPMENTS 213 18 QUESTIONNAIRE 214 19 RELATED REPORTS 217 List of Tables/GraphsLIST OF TABLESTABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 58 TABLE 2 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 75 TABLE 3 MIDDLE EAST & AFRICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 76 TABLE 4 MIDDLE EAST & AFRICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 76 TABLE 5 MIDDLE EAST & AFRICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 78 TABLE 6 MIDDLE EAST & AFRICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 78 TABLE 7 MIDDLE EAST & AFRICA CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 79 TABLE 8 MIDDLE EAST & AFRICA BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80 TABLE 9 MIDDLE EAST & AFRICA GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80 TABLE 10 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81 TABLE 11 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 85 TABLE 12 MIDDLE EAST & AFRICA MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 86 TABLE 13 MIDDLE EAST & AFRICA COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 87 TABLE 14 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 91 TABLE 15 MIDDLE EAST & AFRICA SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 92 TABLE 16 MIDDLE EAST & AFRICA INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 93 TABLE 17 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 97 TABLE 18 MIDDLE EAST & AFRICA PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 98 TABLE 19 MIDDLE EAST & AFRICA SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 99 TABLE 20 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 103 TABLE 21 MIDDLE EAST & AFRICA HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 104 TABLE 22 MIDDLE EAST & AFRICA RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 105 TABLE 23 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 105 TABLE 24 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 106 TABLE 25 MIDDLE EAST & AFRICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 110 TABLE 26 MIDDLE EAST & AFRICA HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 111 TABLE 27 MIDDLE EAST & AFRICA RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 112 TABLE 28 MIDDLE EAST & AFRICA ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 112 TABLE 29 MIDDLE EAST & AFRICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 113 TABLE 30 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 118 TABLE 31 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 118 TABLE 32 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 118 TABLE 33 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 118 TABLE 34 MIDDLE EAST AND AFRICA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119 TABLE 35 MIDDLE EAST AND AFRICA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119 TABLE 36 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 119 TABLE 37 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 120 TABLE 38 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 120 TABLE 39 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 120 TABLE 40 MIDDLE EAST AND AFRICA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 120 TABLE 41 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121 TABLE 42 SOUTH AFRICA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 121 TABLE 43 SOUTH AFRICA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 122 TABLE 44 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 122 TABLE 45 SOUTH AFRICA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 122 TABLE 46 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 122 TABLE 47 SOUTH AFRICA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123 TABLE 48 SOUTH AFRICA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123 TABLE 49 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 123 TABLE 50 SOUTH AFRICA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123 TABLE 51 SOUTH AFRICA SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124 TABLE 52 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 124 TABLE 53 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124 TABLE 54 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 124 TABLE 55 SOUTH AFRICA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125 TABLE 56 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125 TABLE 57 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 125 TABLE 58 SOUTH AFRICA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125 TABLE 59 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125 TABLE 60 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126 TABLE 61 SOUTH AFRICA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 126 TABLE 62 SOUTH AFRICA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 126 TABLE 63 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126 TABLE 64 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126 TABLE 65 SOUTH AFRICA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127 TABLE 66 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127 TABLE 67 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 127 TABLE 68 SOUTH AFRICA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127 TABLE 69 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127 TABLE 70 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128 TABLE 71 SOUTH AFRICA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128 TABLE 72 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 129 TABLE 73 SAUDI ARABIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 129 TABLE 74 SAUDI ARABIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 130 TABLE 75 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 130 TABLE 76 SAUDI ARABIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 130 TABLE 77 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 130 TABLE 78 SAUDI ARABIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131 TABLE 79 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 131 TABLE 80 SAUDI ARABIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131 TABLE 81 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 131 TABLE 82 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132 TABLE 83 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 132 TABLE 84 SAUDI ARABIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 132 TABLE 85 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132 TABLE 86 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 132 TABLE 87 SAUDI ARABIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133 TABLE 88 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133 TABLE 89 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133 TABLE 90 SAUDI ARABIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133 TABLE 91 SAUDI ARABIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 133 TABLE 92 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134 TABLE 93 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134 TABLE 94 SAUDI ARABIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134 TABLE 95 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134 TABLE 96 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134 TABLE 97 SAUDI ARABIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134 TABLE 98 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135 TABLE 99 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 135 TABLE 100 SAUDI ARABIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 135 TABLE 101 EGYPT G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 136 TABLE 102 EGYPT NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 136 TABLE 103 EGYPT ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 137 TABLE 104 EGYPT G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 137 TABLE 105 EGYPT MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 137 TABLE 106 EGYPT G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 137 TABLE 107 EGYPT SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138 TABLE 108 EGYPT G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 138 TABLE 109 EGYPT PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138 TABLE 110 EGYPT G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 138 TABLE 111 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139 TABLE 112 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 139 TABLE 113 EGYPT HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 139 TABLE 114 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139 TABLE 115 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140 TABLE 116 EGYPT RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140 TABLE 117 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140 TABLE 118 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140 TABLE 119 EGYPT AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140 TABLE 120 EGYPT G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 141 TABLE 121 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 141 TABLE 122 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141 TABLE 123 EGYPT HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 141 TABLE 124 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142 TABLE 125 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 142 TABLE 126 EGYPT RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 142 TABLE 127 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142 TABLE 128 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 143 TABLE 129 EGYPT ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 143 TABLE 130 ISRAEL G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 144 TABLE 131 ISRAEL NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 144 TABLE 132 ISRAEL ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 145 TABLE 133 ISRAEL G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 145 TABLE 134 ISRAEL MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 145 TABLE 135 ISRAEL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 145 TABLE 136 ISRAEL SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146 TABLE 137 ISRAEL INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146 TABLE 138 ISRAEL G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 146 TABLE 139 ISRAEL PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 146 TABLE 140 ISRAEL G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 147 TABLE 141 ISRAEL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 147
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Data Bridge Market Research社の医療分野での最新刊レポート本レポートと同じKEY WORD(mea)の最新刊レポートよくあるご質問Data Bridge Market Research社はどのような調査会社ですか?データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/18 10:27 154.74 円 162.88 円 199.42 円 |